Variable | OS | LRRFS | DMFS | DFS | ||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Gender (males vs. females) | 0.63 (0.32–1.26) | 0.191 | 1.25 (0.55–2.85) | 0.588 | 0.50 (0.22–1.11) | 0.087 | 0.71 (0.39–1.30) | 0.265 |
Age (<50 vs. ≥50 years) | 1.92 (1.17–3.15) | 0.010 | 1.31 (0.62–2.77) | 0.486 | 1.59 (0.93–2.72) | 0.092 | 1.70 (1.08–2.67) | 0.022 |
WHO histology (Type II vs. Type III) | 1.87 (0.67–5.21) | 0.229 | 1.54 (0.36–6.50) | 0.561 | 1.59 (0.57–4.44) | 0.379 | 1.22 (0.77–1.92) | 0.433 |
T stage (T1–2 vs. T3–4) | 1.39 (0.52–3.67) | 0.512 | 5.69 (071–45.81) | 0.102 | 1.00 (0.39–2.59) | 0.999 | 1.36 (0.58–3.19) | 0.475 |
N stage (N0–1 vs. N2–3) | 1.36 (0.79–2.37) | 0.270 | 1.13 (0.51–2.47) | 0.768 | 1.59 (0.88–2.87) | 0.126 | 1.29 (0.78–2.13) | 0.322 |
Overall stage (III vs. IV) | 2.50 (1.47–4.26) | 0.001 | 1.05 (0.51–2.17) | 0.897 | 2.54 (1.41–4.58) | 0.002 | 1.80 (1.12–2.89) | 0.016 |
Treatment (NAC + IMRT vs. CCRT + AC) | 1.23 (0.74–2.03) | 0.426 | 1.34 (0.65–2.77) | 0.436 | 1.35 (0.78–2.32) | 0.281 | 1.40 (0.60–3.25) | 0.397 |